Life Sciences Technology Traditional
 
Philosophy  
 

We are seeking opportunities that meet the following investment criteria:

Series A and Series B Financing Rounds
For therapeutics, we prefer to invest in companies with defined clinical assets, but will consider investment opportunities at the pre-clinical stage of development. For diagnostic and medical device products, we predominantly invest in companies with an established “proof-of-principle.”

Personalized Products
The future of medicine is tightly linked to products aligned with reimbursement dynamics and cost containment positioning. Predominantly investing in products defined as “personalized medicine,” we invest in companies developing targeted therapeutics, diagnostic products and platforms, as well as unique breakthrough medical technologies.

 


Top Quality Management
Drawing from our operational experience, we are well-positioned to assess management teams, focusing on their quality, track record, and demonstrated motivation to succeed. If warranted, we will actively assist in recruiting management from our broad base of contacts.

Robust Market Potential
We invest in companies with products that have sufficient market potential to generate required returns. In particular, the market size and growth prospects for those products must be sufficiently robust.

Distinguishable Point of Differentiation in the Marketplace
Companies must possess unique attributes such as a significant market niche or proven technology that creates a competitive advantage, preferably in a sector where barriers to competitive entry exist. This includes such characteristics as targeted evidence-based products, highly proprietary products, and products compatible with an efficient use of paid-in-capital with achievable development and/or approval milestones - within a reasonable time frame.

Superior Financial Returns
We invest in companies capable of generating superior financial returns through an assessment of market potential, competition, overall investment required and exit timeline. Most investments will be distributed in stages that are milestone based. Also, we execute on a life cycle investing practice maintaining pro-rata positions through until exit.

Exit Focus
We believe risk can be minimized and returns maximized, by investing in companies that remain focused on a timely exit strategy.  Therefore management and other investors must be aligned with our exit strategy and execution plan.  Our team will consider an exit in the form of an initial public offering or a trade sale.